Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19
In response to the COVID-19 pandemic, significant public funds have been invested worldwide into the research, development, and manufacturing of pharmaceutical products to combat the novel coronavirus. Traditionally, intellectual property (IP) rights have been justified in the pharmaceutical sector...
Saved in:
Main Author: | Helen Yu BSc, JD, PhD |
---|---|
Format: | article |
Language: | EN |
Published: |
SAGE Publishing
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/3c325e7f15c64ba1b3d4d978dde48b92 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Measuring the COVID-19 Financial Threat to Hospital Markets
by: Anthony W. Orlando MSc, PhD, et al.
Published: (2021) -
The Psychological Benefits of COVID-19 Vaccination
by: My Nguyen
Published: (2021) -
Gender Differences in the Factors Associated With the Fear of COVID-19 Among Taiwanese Older People
by: Yueh-Ping Li PhD, et al.
Published: (2021) -
The urgent need of public policies for promoting cardiovascular health in Latin-American women
by: Pamela Seron, Ph.D, et al.
Published: (2021) -
Recent Advances on Drugs and Vaccines for COVID-19
by: Fang Peng MD, et al.
Published: (2021)